Proton-Coupled Organic Cation Antiporter-Mediated Uptake of Apomorphine Enantiomers in Human Brain Capillary Endothelial Cell Line hCMEC/D3

R(−)-Apomorphine is a dopamine agonist used for rescue management of motor function impairment associated with levodopa therapy in Parkinson’s disease patients. The aim of this study was to examine the role of proton-coupled organic cation antiporter in uptake of R(−)-apomorphine and its S-enantiome...

Full description

Saved in:
Bibliographic Details
Published inBiological & pharmaceutical bulletin Vol. 37; no. 2; pp. 286 - 291
Main Authors Okura, Takashi, Higuchi, Kei, Kitamura, Atsushi, Deguchi, Yoshiharu
Format Journal Article
LanguageEnglish
Published Japan The Pharmaceutical Society of Japan 01.02.2014
Pharmaceutical Society of Japan
Japan Science and Technology Agency
Subjects
Online AccessGet full text

Cover

Loading…
Abstract R(−)-Apomorphine is a dopamine agonist used for rescue management of motor function impairment associated with levodopa therapy in Parkinson’s disease patients. The aim of this study was to examine the role of proton-coupled organic cation antiporter in uptake of R(−)-apomorphine and its S-enantiomer in human brain, using human endothelial cell line hCMEC/D3 as a model. Uptake of R(−)- or S(+)-apomorphine into hCMEC/D3 cells was measured under various conditions to evaluate its time-, concentration-, energy- and ion-dependency. Inhibition by selected organic cations was also examined. Uptakes of both R(−)- and S(+)-apomorphine increased with time. The initial uptake velocities of R(−)- and S(+)-apomorphine were concentration-dependent, with similar Km and Vmax values. The cell-to-medium (C/M) ratio of R(−)-apomorphine was significantly reduced by pretreatment with sodium azide, but was not affected by replacement of extracellular sodium ion with N-methylglucamine or potassium. Intracellular alkalization markedly reduced the uptake, while intracellular acidification increased it, suggesting that the uptake is driven by an oppositely directed proton gradient. The C/M ratio was significantly decreased by amantadine, verapamil, pyrilamine and diphenhydramine (substrates or inhibitors of proton-coupled organic cation antiporter), while tetraethylammonium (substrate of organic cation transporters (OCTs)) and carnitine (substrate of carnitine/organic cation transporter 2; (OCTN2)) had no effect. R(−)-Apomorphine uptake was competitively inhibited by diphenhydramine. Our results indicate that R(−)-apomorphine transport in human blood–brain barrier (BBB) model cells is similar to S(+)-apomorphine uptake. The transport was dependent on an oppositely directed proton gradient, but was sodium- or membrane potential-independent. The transport characteristics were consistent with involvement of the previously reported proton-coupled organic cation antiporter.
AbstractList R(-)-Apomorphine is a dopamine agonist used for rescue management of motor function impairment associated with levodopa therapy in Parkinson's disease patients. The aim of this study was to examine the role of proton-coupled organic cation antiporter in uptake of R(-)-apomorphine and its S-enantiomer in human brain, using human endothelial cell line hCMEC/D3 as a model. Uptake of R(-)- or S(+)-apomorphine into hCMEC/D3 cells was measured under various conditions to evaluate its time-, concentration-, energy- and ion-dependency. Inhibition by selected organic cations was also examined. Uptakes of both R(-)- and S(+)-apomorphine increased with time. The initial uptake velocities of R(-)- and S(+)-apomorphine were concentration-dependent, with similar Km and Vmax values. The cell-to-medium (C/M) ratio of R(-)-apomorphine was significantly reduced by pretreatment with sodium azide, but was not affected by replacement of extracellular sodium ion with N-methylglucamine or potassium. Intracellular alkalization markedly reduced the uptake, while intracellular acidification increased it, suggesting that the uptake is driven by an oppositely directed proton gradient. The C/M ratio was significantly decreased by amantadine, verapamil, pyrilamine and diphenhydramine (substrates or inhibitors of proton-coupled organic cation antiporter), while tetraethylammonium (substrate of organic cation transporters (OCTs)) and carnitine (substrate of carnitine/organic cation transporter 2; (OCTN2)) had no effect. R(-)-Apomorphine uptake was competitively inhibited by diphenhydramine. Our results indicate that R(-)-apomorphine transport in human blood-brain barrier (BBB) model cells is similar to S(+)-apomorphine uptake. The transport was dependent on an oppositely directed proton gradient, but was sodium- or membrane potential-independent. The transport characteristics were consistent with involvement of the previously reported proton-coupled organic cation antiporter.
R(-)-Apomorphine is a dopamine agonist used for rescue management of motor function impairment associated with levodopa therapy in Parkinson's disease patients. The aim of this study was to examine the role of proton-coupled organic cation antiporter in uptake of R(-)-apomorphine and its S-enantiomer in human brain, using human endothelial cell line hCMEC/D3 as a model. Uptake of R(-)- or S(+)-apomorphine into hCMEC/D3 cells was measured under various conditions to evaluate its time-, concentration-, energy- and ion-dependency. Inhibition by selected organic cations was also examined. Uptakes of both R(-)- and S(+)-apomorphine increased with time. The initial uptake velocities of R(-)- and S(+)-apomorphine were concentration-dependent, with similar Km and Vmax values. The cell-to-medium (C/M) ratio of R(-)-apomorphine was significantly reduced by pretreatment with sodium azide, but was not affected by replacement of extracellular sodium ion with N-methylglucamine or potassium. Intracellular alkalization markedly reduced the uptake, while intracellular acidification increased it, suggesting that the uptake is driven by an oppositely directed proton gradient. The C/M ratio was significantly decreased by amantadine, verapamil, pyrilamine and diphenhydramine (substrates or inhibitors of proton-coupled organic cation antiporter), while tetraethylammonium (substrate of organic cation transporters (OCTs)) and carnitine (substrate of carnitine/organic cation transporter 2; (OCTN2)) had no effect. R(-)-Apomorphine uptake was competitively inhibited by diphenhydramine. Our results indicate that R(-)-apomorphine transport in human blood-brain barrier (BBB) model cells is similar to S(+)-apomorphine uptake. The transport was dependent on an oppositely directed proton gradient, but was sodium- or membrane potential-independent. The transport characteristics were consistent with involvement of the previously reported proton-coupled organic cation antiporter.R(-)-Apomorphine is a dopamine agonist used for rescue management of motor function impairment associated with levodopa therapy in Parkinson's disease patients. The aim of this study was to examine the role of proton-coupled organic cation antiporter in uptake of R(-)-apomorphine and its S-enantiomer in human brain, using human endothelial cell line hCMEC/D3 as a model. Uptake of R(-)- or S(+)-apomorphine into hCMEC/D3 cells was measured under various conditions to evaluate its time-, concentration-, energy- and ion-dependency. Inhibition by selected organic cations was also examined. Uptakes of both R(-)- and S(+)-apomorphine increased with time. The initial uptake velocities of R(-)- and S(+)-apomorphine were concentration-dependent, with similar Km and Vmax values. The cell-to-medium (C/M) ratio of R(-)-apomorphine was significantly reduced by pretreatment with sodium azide, but was not affected by replacement of extracellular sodium ion with N-methylglucamine or potassium. Intracellular alkalization markedly reduced the uptake, while intracellular acidification increased it, suggesting that the uptake is driven by an oppositely directed proton gradient. The C/M ratio was significantly decreased by amantadine, verapamil, pyrilamine and diphenhydramine (substrates or inhibitors of proton-coupled organic cation antiporter), while tetraethylammonium (substrate of organic cation transporters (OCTs)) and carnitine (substrate of carnitine/organic cation transporter 2; (OCTN2)) had no effect. R(-)-Apomorphine uptake was competitively inhibited by diphenhydramine. Our results indicate that R(-)-apomorphine transport in human blood-brain barrier (BBB) model cells is similar to S(+)-apomorphine uptake. The transport was dependent on an oppositely directed proton gradient, but was sodium- or membrane potential-independent. The transport characteristics were consistent with involvement of the previously reported proton-coupled organic cation antiporter.
R(−)-Apomorphine is a dopamine agonist used for rescue management of motor function impairment associated with levodopa therapy in Parkinson’s disease patients. The aim of this study was to examine the role of proton-coupled organic cation antiporter in uptake of R(−)-apomorphine and its S-enantiomer in human brain, using human endothelial cell line hCMEC/D3 as a model. Uptake of R(−)- or S(+)-apomorphine into hCMEC/D3 cells was measured under various conditions to evaluate its time-, concentration-, energy- and ion-dependency. Inhibition by selected organic cations was also examined. Uptakes of both R(−)- and S(+)-apomorphine increased with time. The initial uptake velocities of R(−)- and S(+)-apomorphine were concentration-dependent, with similar Km and Vmax values. The cell-to-medium (C/M) ratio of R(−)-apomorphine was significantly reduced by pretreatment with sodium azide, but was not affected by replacement of extracellular sodium ion with N-methylglucamine or potassium. Intracellular alkalization markedly reduced the uptake, while intracellular acidification increased it, suggesting that the uptake is driven by an oppositely directed proton gradient. The C/M ratio was significantly decreased by amantadine, verapamil, pyrilamine and diphenhydramine (substrates or inhibitors of proton-coupled organic cation antiporter), while tetraethylammonium (substrate of organic cation transporters (OCTs)) and carnitine (substrate of carnitine/organic cation transporter 2; (OCTN2)) had no effect. R(−)-Apomorphine uptake was competitively inhibited by diphenhydramine. Our results indicate that R(−)-apomorphine transport in human blood–brain barrier (BBB) model cells is similar to S(+)-apomorphine uptake. The transport was dependent on an oppositely directed proton gradient, but was sodium- or membrane potential-independent. The transport characteristics were consistent with involvement of the previously reported proton-coupled organic cation antiporter.
Author Okura, Takashi
Higuchi, Kei
Deguchi, Yoshiharu
Kitamura, Atsushi
Author_xml – sequence: 1
  fullname: Okura, Takashi
  organization: Laboratory of Drug Disposition & Pharmacokinetics, Faculty of Pharma-Sciences, Teikyo University
– sequence: 2
  fullname: Higuchi, Kei
  organization: Laboratory of Drug Disposition & Pharmacokinetics, Faculty of Pharma-Sciences, Teikyo University
– sequence: 3
  fullname: Kitamura, Atsushi
  organization: Laboratory of Drug Disposition & Pharmacokinetics, Faculty of Pharma-Sciences, Teikyo University
– sequence: 4
  fullname: Deguchi, Yoshiharu
  organization: Laboratory of Drug Disposition & Pharmacokinetics, Faculty of Pharma-Sciences, Teikyo University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24257040$$D View this record in MEDLINE/PubMed
BookMark eNp1krtuFDEUhi0URDaBkhZZoqGZxLe5lcuwJEgbhYLUlsf2ZL147MH2FHkGXhrPblikSDS-6HznnN_n9wU4c95pAN5jdIUJa677qb_qMS0Qqmv6CqwwZXVRElyegRVqcVNUuGzOwUWMe5QZROgbcE4YKWvE0Ar8_h588q7o_DxZreB9eBTOSNiJZLyDa5fM5EPSobjTyoiUkYcpiZ8a-gGuJz_6MO2M03DjRGb9qEOExsHbeRQOfg4inzsxGWtFeMqQ8mmnrREWdtpauF1Sd93dprv-Qt-C14OwUb973i_Bw9fNj-622N7ffOvW20LWrEqFGvqhElJVhJQKUzm0CAvV5iBtkMS9Ik1PsBZMI4WrUjat6kvc5JvQFWGSXoJPx7pT8L9mHRMfTZRZjnDaz5Fj1rYYt02JMvrxBbr3c3BZ3UKxitUVWagPz9Tcj1rxKZgxP5f_HXMGiiMgg48x6OGEYMQXG3m2kWcb-cHGzNMXvDTp4EjKE7X_zbo5ZmUNRgrrnc3j_adYxro33npOEGY5h-bfwBGuOCLNsrSYENzW9aK3O1baxyQe9UmtCMlIqw99ac3Jspz6n6JyJwLXjv4BBevPiQ
CitedBy_id crossref_primary_10_4062_biomolther_2019_007
crossref_primary_10_1016_j_xphs_2017_05_007
crossref_primary_10_1080_17425247_2025_2462767
crossref_primary_10_1016_j_pharmthera_2022_108283
crossref_primary_10_1002_jps_24691
crossref_primary_10_1021_mp500516j
crossref_primary_10_1124_dmd_123_001354
crossref_primary_10_3390_pharmaceutics14081683
crossref_primary_10_47493_abantmedj_1584839
crossref_primary_10_1002_bdd_2014
crossref_primary_10_1242_dmm_049410
crossref_primary_10_1016_j_xphs_2017_04_032
crossref_primary_10_1016_j_xphs_2016_10_006
crossref_primary_10_1007_s11064_016_2030_x
crossref_primary_10_1248_bpb_b24_00329
crossref_primary_10_1007_s11095_022_03223_z
crossref_primary_10_1124_dmd_115_068932
crossref_primary_10_1248_yakushi_14_00234_2
crossref_primary_10_1021_jm500786c
crossref_primary_10_3390_molecules26185629
crossref_primary_10_1016_j_neuint_2014_04_015
crossref_primary_10_1016_j_jconrel_2017_03_034
crossref_primary_10_1016_j_xphs_2020_09_001
Cites_doi 10.1002/syn.890150403
10.2133/dmpk.DMPK-13-RG-058
10.1152/ajpgi.2000.278.4.G563
10.1186/2045-8118-10-8
ContentType Journal Article
Copyright 2014 The Pharmaceutical Society of Japan
Copyright Japan Science and Technology Agency 2014
Copyright_xml – notice: 2014 The Pharmaceutical Society of Japan
– notice: Copyright Japan Science and Technology Agency 2014
CorporateAuthor Teikyo University
Faculty of Pharma-Sciences
Laboratory of Drug Disposition & Pharmacokinetics
CorporateAuthor_xml – name: Laboratory of Drug Disposition & Pharmacokinetics
– name: Faculty of Pharma-Sciences
– name: Teikyo University
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7QR
7TK
7U9
8FD
FR3
H94
P64
7X8
DOI 10.1248/bpb.b13-00773
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Neurosciences Abstracts
Virology and AIDS Abstracts
Technology Research Database
Engineering Research Database
AIDS and Cancer Research Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Virology and AIDS Abstracts
Technology Research Database
AIDS and Cancer Research Abstracts
Chemoreception Abstracts
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic


Virology and AIDS Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Chemistry
Pharmacy, Therapeutics, & Pharmacology
EISSN 1347-5215
EndPage 291
ExternalDocumentID 3206545581
24257040
10_1248_bpb_b13_00773
cs7biolo_2014_003702_016_0286_02912219770
article_bpb_37_2_37_b13_00773_article_char_en
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
23N
2WC
53G
5GY
6J9
ACGFO
ACIWK
ACPRK
ADBBV
AENEX
AFFNX
AFRAH
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BKOMP
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
GX1
HH5
JMI
JSF
JSH
KQ8
MOJWN
OK1
P2P
RJT
RZJ
TR2
XSB
ABJNI
.55
1CY
AAYXX
AI.
CITATION
TKC
VH1
X7M
ZXP
ZY4
ABTAH
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7QR
7TK
7U9
8FD
FR3
H94
P64
7X8
ID FETCH-LOGICAL-c746t-dfbf6acd6225d13cf901ad9c74380c1bd28b21ea4e0d165c89db518e0dae624c3
ISSN 0918-6158
1347-5215
IngestDate Fri Jul 11 02:19:36 EDT 2025
Mon Jun 30 10:06:21 EDT 2025
Thu May 23 23:51:55 EDT 2024
Tue Jul 01 02:43:49 EDT 2025
Thu Apr 24 23:02:55 EDT 2025
Thu Jul 10 16:12:41 EDT 2025
Thu Aug 17 20:29:54 EDT 2023
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c746t-dfbf6acd6225d13cf901ad9c74380c1bd28b21ea4e0d165c89db518e0dae624c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://www.jstage.jst.go.jp/article/bpb/37/2/37_b13-00773/_article/-char/en
PMID 24257040
PQID 1494647620
PQPubID 1966364
PageCount 6
ParticipantIDs proquest_miscellaneous_1499119850
proquest_journals_1494647620
pubmed_primary_24257040
crossref_primary_10_1248_bpb_b13_00773
crossref_citationtrail_10_1248_bpb_b13_00773
medicalonline_journals_cs7biolo_2014_003702_016_0286_02912219770
jstage_primary_article_bpb_37_2_37_b13_00773_article_char_en
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2014-02-01
PublicationDateYYYYMMDD 2014-02-01
PublicationDate_xml – month: 02
  year: 2014
  text: 2014-02-01
  day: 01
PublicationDecade 2010
PublicationPlace Japan
PublicationPlace_xml – name: Japan
– name: Tokyo
PublicationTitle Biological & pharmaceutical bulletin
PublicationTitleAlternate Biol Pharm Bull
PublicationYear 2014
Publisher The Pharmaceutical Society of Japan
Pharmaceutical Society of Japan
Japan Science and Technology Agency
Publisher_xml – name: The Pharmaceutical Society of Japan
– name: Pharmaceutical Society of Japan
– name: Japan Science and Technology Agency
References 5)  Boström E, Simonsson US, Hammarlund-Udenaes M. In vivo blood–brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Metab. Dispos., 34, 1624–1631 (2006).
9)  Kuwayama K, Inoue H, Kanamori T, Tsujikawa K, Miyaguchi H, Iwata Y, Miyauchi S, Kamo N, Kishi T. Uptake of 3,4-methylenedioxymethamphetamine and its related compounds by a proton-coupled transport system in Caco-2 cells. Biochim. Biophys. Acta, 1778, 42–50 (2008).
2)  Weksler BB, Subileau EA, Perrière N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F, Greenwood J, Romero IA, Couraud PO. Blood–brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J., 19, 1872–1874 (2005).
13)  Okura T, Ito R, Ishiguro N, Tamai I, Deguchi Y. Blood–brain barrier transport of pramipexole, a dopamine D2 agonist. Life Sci., 80, 1564–1571 (2007).
15)  Cisternino S, Chapy H, André P, Smirnova M, Debray M, Scherrmann JM. Coexistence of passive and proton antiporter-mediated processes in nicotine transport at the mouse blood–brain barrier. AAPS J., 15, 299–307 (2013).
16)  Tega Y, Akanuma S, Kubo Y, Terasaki T, Hosoya K. Blood-to-brain influx transport of nicotine at the rat blood–brain barrier: involvement of a pyrilamine-sensitive organic cation transport process. Neurochem. Int., 62, 173–181 (2013).
3)  Weksler B, Romero IA, Couraud PO. The hCMEC/D3 cell line as a model of the human blood brain barrier. Fluids and Barriers of the CNS, 10, 16 (2013).
10)  André P, Debray M, Scherrmann JM, Cisternino S. Clonidine transport at the mouse blood–brain barrier by a new H+ antiporter that interacts with addictive drugs. J. Cereb. Blood Flow Metab., 29, 1293–1304 (2009).
12)  Szabo Z, Ravert HT, Gözükara I, Geckle W, Seki C, Sostre S, Peller P, Monsein L, Natarajan TK, Links JM, Wong DF, Dannals RF, Wagner HN Jr. Noncompartmental and compartmental modeling of the kinetics of carbon-11 labeled pyrilamine in the human brain. Synapse, 15, 263–275 (1993).
1)  Sam E, Sarre S, Michotte Y, Verbeke N. Distribution of apomorphine enantiomers in plasma, brain tissue and striatal extracellular fluid. Eur. J. Pharmacol., 329, 9–15 (1997).
17)  Armstrong J, Barlow RB. The ionization of phenolic amines, including apomorphine, dopamine and catecholamines and an assessment of zwitterion constants. Br. J. Pharmacol., 57, 501–516 (1976).
8)  Okura T, Kato S, Deguchi Y. Functional expression of organic cation/carnitine transporter 2 (OCTN2/SLC22A5) in human brain capillary endothelial cell line hCMEC/D3, a human blood–brain barrier model. Drug Metab. Pharmacokinet., 2013, in press.
4)  Shimomura K, Okura T, Kato S, Couraud PO, Schermann JM, Terasaki T, Deguchi Y. Functional expression of a proton-coupled organic cation (H+/OC) antiporter in human brain capillary endothelial cell line hCMEC/D3, a human blood–brain barrier model. Fluids and Barriers of the CNS, 10, 8 (2013).
11)  Kubo Y, Shimizu Y, Kusagawa Y, Akanuma S, Hosoya K. Propranolol transport across the inner blood–retinal barrier: potential involvement of a novel organic cation transporter. J. Pharm. Sci., 102, 3332–3342 (2013).
6)  Okura T, Hattori A, Takano Y, Sato T, Hammarlund-Udenaes M, Terasaki T, Deguchi Y. Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood–brain barrier transport of oxycodone. Drug Metab. Dispos., 36, 2005–2013 (2008).
14)  Mizuuchi H, Katsura T, Ashida K, Hashimoto Y, Inui KI. Diphenhydramine transport by pH-dependent tertiary amine transport system in Caco-2 cells. Am. J. Physiol. Gastrointest. Liver Physiol., 278, G563–G569 (2000).
7)  Sadiq MW, Borgs A, Okura T, Shimomura K, Kato S, Deguchi Y, Jansson B, Björkman S, Terasaki T, Hammarlund-Udenaes M. Diphenhydramine active uptake at the blood–brain barrier and its interaction with oxycodone in vitro and in vivo. J. Pharm. Sci., 100, 3912–3923 (2011).
11
12
13
14
15
16
17
1
2
3
4
5
6
7
8
9
10
References_xml – reference: 7)  Sadiq MW, Borgs A, Okura T, Shimomura K, Kato S, Deguchi Y, Jansson B, Björkman S, Terasaki T, Hammarlund-Udenaes M. Diphenhydramine active uptake at the blood–brain barrier and its interaction with oxycodone in vitro and in vivo. J. Pharm. Sci., 100, 3912–3923 (2011).
– reference: 6)  Okura T, Hattori A, Takano Y, Sato T, Hammarlund-Udenaes M, Terasaki T, Deguchi Y. Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood–brain barrier transport of oxycodone. Drug Metab. Dispos., 36, 2005–2013 (2008).
– reference: 13)  Okura T, Ito R, Ishiguro N, Tamai I, Deguchi Y. Blood–brain barrier transport of pramipexole, a dopamine D2 agonist. Life Sci., 80, 1564–1571 (2007).
– reference: 17)  Armstrong J, Barlow RB. The ionization of phenolic amines, including apomorphine, dopamine and catecholamines and an assessment of zwitterion constants. Br. J. Pharmacol., 57, 501–516 (1976).
– reference: 2)  Weksler BB, Subileau EA, Perrière N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F, Greenwood J, Romero IA, Couraud PO. Blood–brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J., 19, 1872–1874 (2005).
– reference: 12)  Szabo Z, Ravert HT, Gözükara I, Geckle W, Seki C, Sostre S, Peller P, Monsein L, Natarajan TK, Links JM, Wong DF, Dannals RF, Wagner HN Jr. Noncompartmental and compartmental modeling of the kinetics of carbon-11 labeled pyrilamine in the human brain. Synapse, 15, 263–275 (1993).
– reference: 11)  Kubo Y, Shimizu Y, Kusagawa Y, Akanuma S, Hosoya K. Propranolol transport across the inner blood–retinal barrier: potential involvement of a novel organic cation transporter. J. Pharm. Sci., 102, 3332–3342 (2013).
– reference: 3)  Weksler B, Romero IA, Couraud PO. The hCMEC/D3 cell line as a model of the human blood brain barrier. Fluids and Barriers of the CNS, 10, 16 (2013).
– reference: 16)  Tega Y, Akanuma S, Kubo Y, Terasaki T, Hosoya K. Blood-to-brain influx transport of nicotine at the rat blood–brain barrier: involvement of a pyrilamine-sensitive organic cation transport process. Neurochem. Int., 62, 173–181 (2013).
– reference: 1)  Sam E, Sarre S, Michotte Y, Verbeke N. Distribution of apomorphine enantiomers in plasma, brain tissue and striatal extracellular fluid. Eur. J. Pharmacol., 329, 9–15 (1997).
– reference: 9)  Kuwayama K, Inoue H, Kanamori T, Tsujikawa K, Miyaguchi H, Iwata Y, Miyauchi S, Kamo N, Kishi T. Uptake of 3,4-methylenedioxymethamphetamine and its related compounds by a proton-coupled transport system in Caco-2 cells. Biochim. Biophys. Acta, 1778, 42–50 (2008).
– reference: 4)  Shimomura K, Okura T, Kato S, Couraud PO, Schermann JM, Terasaki T, Deguchi Y. Functional expression of a proton-coupled organic cation (H+/OC) antiporter in human brain capillary endothelial cell line hCMEC/D3, a human blood–brain barrier model. Fluids and Barriers of the CNS, 10, 8 (2013).
– reference: 15)  Cisternino S, Chapy H, André P, Smirnova M, Debray M, Scherrmann JM. Coexistence of passive and proton antiporter-mediated processes in nicotine transport at the mouse blood–brain barrier. AAPS J., 15, 299–307 (2013).
– reference: 5)  Boström E, Simonsson US, Hammarlund-Udenaes M. In vivo blood–brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Metab. Dispos., 34, 1624–1631 (2006).
– reference: 10)  André P, Debray M, Scherrmann JM, Cisternino S. Clonidine transport at the mouse blood–brain barrier by a new H+ antiporter that interacts with addictive drugs. J. Cereb. Blood Flow Metab., 29, 1293–1304 (2009).
– reference: 8)  Okura T, Kato S, Deguchi Y. Functional expression of organic cation/carnitine transporter 2 (OCTN2/SLC22A5) in human brain capillary endothelial cell line hCMEC/D3, a human blood–brain barrier model. Drug Metab. Pharmacokinet., 2013, in press.
– reference: 14)  Mizuuchi H, Katsura T, Ashida K, Hashimoto Y, Inui KI. Diphenhydramine transport by pH-dependent tertiary amine transport system in Caco-2 cells. Am. J. Physiol. Gastrointest. Liver Physiol., 278, G563–G569 (2000).
– ident: 2
– ident: 12
  doi: 10.1002/syn.890150403
– ident: 17
– ident: 3
– ident: 5
– ident: 8
  doi: 10.2133/dmpk.DMPK-13-RG-058
– ident: 1
– ident: 11
– ident: 10
– ident: 13
– ident: 14
  doi: 10.1152/ajpgi.2000.278.4.G563
– ident: 16
– ident: 4
  doi: 10.1186/2045-8118-10-8
– ident: 15
– ident: 6
– ident: 9
– ident: 7
SSID ssj0007023
ssib058492369
ssib023156946
ssib002483627
ssib002822050
ssib017383521
Score 2.1907063
Snippet R(−)-Apomorphine is a dopamine agonist used for rescue management of motor function impairment associated with levodopa therapy in Parkinson’s disease...
R(-)-Apomorphine is a dopamine agonist used for rescue management of motor function impairment associated with levodopa therapy in Parkinson's disease...
SourceID proquest
pubmed
crossref
medicalonline
jstage
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 286
SubjectTerms Antiporters - metabolism
apomorphine
Apomorphine - pharmacokinetics
Biological Transport
Blood-Brain Barrier - metabolism
blood–brain barrier
Cations - metabolism
Cell Line
Dopamine Agonists - pharmacokinetics
Endothelial Cells - metabolism
hCMEC/D3 cell
Humans
Hydrogen-Ion Concentration
Membrane Potentials
Organic Cation Transport Proteins - metabolism
proton-coupled organic cation antiporter
Protons
Sodium - metabolism
Stereoisomerism
Title Proton-Coupled Organic Cation Antiporter-Mediated Uptake of Apomorphine Enantiomers in Human Brain Capillary Endothelial Cell Line hCMEC/D3
URI https://www.jstage.jst.go.jp/article/bpb/37/2/37_b13-00773/_article/-char/en
http://mol.medicalonline.jp/library/journal/download?GoodsID=cs7biolo/2014/003702/016&name=0286-0291e
https://www.ncbi.nlm.nih.gov/pubmed/24257040
https://www.proquest.com/docview/1494647620
https://www.proquest.com/docview/1499119850
Volume 37
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Biological and Pharmaceutical Bulletin, 2014/02/01, Vol.37(2), pp.286-291
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELfGQAIJIdj4KAxkJLQXli4fzkclHijd0DQY4qGTxlNkx45WuiZVmzyUf4F_mEfu7CRNxiYxeLHa-JzEufs5dxffHSFvhCN5pKS0eMS4xVJPWCLiuBjayncAfYHeTXjyJTg6Zcdn_tnGxq_WrqWyEP3kx5VxJf_CVTgGfMUo2RtwtjkpHIDfwF9ogcPQ_hWPvy5yrAA8ysv5BSiOJq4ywag-ZOowKyY6bfnCOtEFOYDkdF7wqTLqZz7L4SGjlnmIu2EwDn-hd8cax_4HLB4B55pjXaLFCogkRmtdoIt9hB6_zzj0fHRyOIIZHHidz8OTZk3V0QjnHcd5J-U3Oninpa529HbMp1jbqeUOx1ItJnyoOfppUvBZNWBYLMvWgAPVDPiWw3G4bNl2azis3gldCSKC5NLN1dtY4REdgyKRtX2ZTgQ2sMkB31dmJfdYCFa2iRWtl3qTX6YSabe9btf5uM0_U0Dsj7eLyzBiQsxFX2BNDDs0VVguJeyuxCEGutgLYxcboI81fVz3YlAdyPAtctsFA8fVr5S14RbaujBhM7EqOyzcwH7n8h1t6s53MCgwU8T9mfnIZ5KtXG87aR1q_JA8qIwfOjQ394hsqGyLbA8zXuSzFd2lejuy_s6zRe6O6lKEW2S34tFqj47X8YLLPT2kSb2-2iY_u4igFSKoQQS9AhHUIILmKW0hgrYQQScZ1YigGhG0QQRtIYIiIigigmpE7B94j8npx8Px6Miqyo1YSciCwpKpSAOeyABecdLxkhRUZS4H0OlFduII6UbCdRRnypZO4CfRQArfieAfV4HLEu8J2czyTD0jlEkpRZgqN_UThkaYTLijXC_kEvQ_P-yRvZptcVLl4seSMBcx2uTAZS08jdD0yG5DPjdJaK4jfGdkoCG7kTD2yPuO5MTVWreMk2Wok8LFCFXMJwwCGuPmUDBPsBk4Lqg-YWj3yE4tbOvRDhuwgMHCD92vm26QIfw4yTOVl5oG9K5B5APNUyOkzSS0WwS0jef_N70X5N56pdkhm8WiVC_BpCjEK42-399nKmQ
linkProvider ABC ChemistRy
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Proton-Coupled+Organic+Cation+Antiporter-Mediated+Uptake+of+Apomorphine+Enantiomers+in+Human+Brain+Capillary+Endothelial+Cell+Line+hCMEC%2FD3&rft.jtitle=Biological+and+Pharmaceutical+Bulletin&rft.au=Okura%2C+Takashi&rft.au=Higuchi%2C+Kei&rft.au=Kitamura%2C+Atsushi&rft.au=Deguchi%2C+Yoshiharu&rft.date=2014-02-01&rft.pub=The+Pharmaceutical+Society+of+Japan&rft.issn=0918-6158&rft.eissn=1347-5215&rft.volume=37&rft.issue=2&rft.spage=286&rft.epage=291&rft_id=info:doi/10.1248%2Fbpb.b13-00773&rft.externalDocID=article_bpb_37_2_37_b13_00773_article_char_en
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0918-6158&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0918-6158&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0918-6158&client=summon